In vitro studies, applying a COX-2-selective inhibitor to COX-2-positive pancreatic cancer cells, revealed that expression of Notch1, Hes1 and DLL1 depended on COX-2-mediated prostaglandin synthesis. Here, HES1 is linked to pancreatic neoplasm.